Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2020

Mark S. Freedman, DVM; Paul Hunter, MD; Kevin Ault, MD; Andrew Kroger, MD

Disclosures

Morbidity and Mortality Weekly Report. 2020;69(5):133-135. 

In This Article

Changes in the 2020 Adult Immunization Schedule

Changes in the 2020 adult immunization schedule for persons aged ≥19 years include new or revised recommendations for hepatitis A vaccine (HepA);[2] human papillomavirus vaccine (HPV);[3] influenza vaccine;[4] serogroup B meningococcal vaccine (MenB); pneumococcal vaccine;[5] and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap).[6] Following are the changes to the cover page, Table 1, Table 2, and Notes.

Cover Page

  • Trademark symbols (®) were added to all vaccine trade names.

  • PedvaxHIB was added to the table of trade names for Haemophilus influenzae type b vaccine.

  • The footnote on the cover page has been edited and now reads "Do not restart or add doses to vaccine series if there are extended intervals between doses."

Table 1

  • Age ranges: The columns for age groups 19–21 years and 22–26 years have been combined, thereby reducing the number of columns for age ranges from five to four. This change was made because of the change in recommendation for catch-up HPV vaccination for all adults aged ≤26 years.

  • Tetanus, diphtheria, pertussis row: This row has been edited to state that tetanus and diphtheria toxoids (Td) or Tdap may be used for the decennial tetanus booster.

  • Human papillomavirus (HPV) row: The rows for males and females have been combined, reflecting that catch-up vaccination is now recommended for all adults aged ≤26 years. In addition, a blue box has been added for persons aged 27–45 years to indicate that shared clinical decision-making regarding vaccination is now recommended for this group.

  • Pneumococcal conjugate (PCV13) row: The box for persons aged ≥65 years who do not have an additional risk factor or another indication has been changed to blue to indicate that shared clinical decision-making regarding vaccination is now recommended for this group.

  • Meningococcal B (MenB) row: A blue box has been added for persons aged 19–23 years who are not at increased risk for meningococcal disease, indicating that shared clinical decision-making regarding vaccination is now recommended for this group.

  • Legend: A blue box has been added to indicate that shared clinical decision-making is recommended regarding vaccination. The text defining the gray box has been edited and now reads "No recommendation/not applicable."

Table 2

  • Tdap or Td row: This row has been revised to read that Td or Tdap may be used for the decennial tetanus booster.

  • Human Papillomavirus (HPV) row: This row has been combined into a single row including both males and females, reflecting that HPV vaccine is now recommended for all adults aged ≤26 years.

  • Hepatitis A (HepA) row: The box for persons living with human immunodeficiency virus (HIV) infection (regardless of CD4 count) is now yellow, reflecting the new recommendation that previously unvaccinated persons in this group should be vaccinated.

  • Legend and bar text: The gray box in the Legend has been edited and now reads "No recommendation/not applicable." The red box has been edited and now reads "Not recommended/contraindicated — vaccine should not be administered." The text appearing in the red bars has been changed from "Contraindicated" to "Not Recommended."

Notes

  • Edits have been made throughout the Notes section to harmonize language between the child/adolescent immunization schedule and the adult immunization schedule, where possible.

  • A new subsection entitled "Shared Clinical Decision-Making" was added for each vaccine that includes this new ACIP recommendation (e.g., for HPV, PCV13, and MenB).

  • Hepatitis A: The note was revised to include minor changes to the chronic liver disease definition, minor changes for the pregnancy indication, addition of the recommendation for vaccination in settings of exposure, and removal of clotting factor disorders as an indication for vaccination.

  • Hepatitis B: The note was revised to include minor changes to the chronic liver disease definition and minor changes for the pregnancy indication.

  • Human papillomavirus: The note was revised to indicate that HPV vaccination is recommended for all persons aged ≤26 years. A shared clinical decision-making subsection was added for persons aged 27–45 years.

  • Influenza: The note was updated to include a bulleted list indicating when live attenuated influenza vaccine (LAIV) should not be used and minor edits to the guidance for persons with a history of Guillain-Barré syndrome.

  • Measles, mumps, and rubella: The note was revised to clarify recommendations for health care personnel, with a separate bullet for personnel born in 1957 or later with no evidence of immunity and for health care personnel born before 1957 with no evidence of immunity.

  • Meningococcal: The note was revised to include the use of the complement inhibitor ravulizumab as an indication for MenB administration in these patients. A shared clinical decision-making subsection was added that includes a bullet for adolescents and young adults aged 16–23 years who are not at increased risk for meningococcal disease. Under the "Special situations" section, the recommendation to administer a booster dose of MenB 1 year after the primary series and to revaccinate every 2–3 years if the risk remains was added.

  • Pneumococcal: The note has been updated to reflect the updated recommendations for vaccination of immunocompetent (defined as adults without an immunocompromising condition, cerebrospinal fluid leak, or cochlear implants) adults aged ≥65 years. One dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) is still recommended. Shared clinical decision-making is recommended regarding administration of PCV13 to immunocompetent persons aged ≥65 years.

  • Tetanus, diphtheria, and pertussis: The note has been updated to indicate that Td or Tdap may be used in situations where only Td vaccine was indicated for the decennial tetanus, diphtheria, and pertussis booster vaccination, tetanus prophylaxis for wound management, and catch-up vaccination.

  • Varicella: The note has been updated to indicate that vaccination may be considered for persons with HIV infection without evidence of varicella immunity who have CD4 counts ≥200 cells/μL.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....